The efficacy and safety of nivolumab in previously treated advanced non-small-cell lung cancer: a meta-analysis of prospective clinical trials

BACKGROUND: Nivolumab (BMS-936558/ONO-4538) was the first monoclonal antibody targeting programmed death (PD)-1. So far, a number of clinical trials on nivolumab have showed satisfactory efficacy in treating non-small-cell lung cancer (NSCLC). Herein, we present a meta-analysis evaluating the effica...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Jiaxing, Zhang, Yaxiong, Sheng, Jin, Zhang, Hongyu, Fang, Wenfeng, Zhan, Jianhua, Zhou, Ting, Chen, Ying, Liu, Lin, Zhang, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045236/
https://www.ncbi.nlm.nih.gov/pubmed/27713640
http://dx.doi.org/10.2147/OTT.S115262

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045236/
https://www.ncbi.nlm.nih.gov/pubmed/27713640
http://dx.doi.org/10.2147/OTT.S115262

Ejemplares similares